<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Jan. 16, 2019 (HealthDay News) — A new review, published in the Jan. 15 issue of the Journal of the American Medical Association<\/i>, addresses best practices for the evaluation and management of reported penicillin allergies.<\/p>\n
Erica S. Shenoy, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues from the American Academy of Allergy, Asthma & Immunology, the Infectious Diseases Society of America, and the Society for Healthcare Epidemiology of America conducted a review of the literature and of published professional society guidelines to produce a consensus manuscript.<\/p>\n
The authors note that direct amoxicillin challenge is appropriate for patients with low-risk allergy histories, which includes patients having isolated nonallergic symptoms such as gastrointestinal symptoms, patients solely with a family history of a penicillin allergy, patients with symptoms of pruritus without rash, or patients with unknown reactions >10 years ago. Moderate-risk patients, including those with urticaria or other pruritic rashes and reactions with features of Immunoglobulin E-mediated reactions, can be evaluated with penicillin skin testing, which carries a negative predictive value >95 percent and approaches 100 percent when combined with amoxicillin challenge.<\/p>\n
“If such allergies are routinely evaluated, patients will not needlessly avoid the beta-lactams that may be the best treatment for their infection and reduce the development of antibiotic resistance,” a coauthor said in a statement.<\/p>\n
Two authors report copyright on a clinical decision support tool for penicillin allergy evaluation.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n